ReviewInternational journal of nephrology2014
Anti-VEGF Cancer Therapy in Nephrology Practice.
Review in International journal of nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- Article
- Comprehensive review of non-invasive-treatment-related cardiovascular toxicity in breast cancer.iScience · 2025Review
- Renal Implications of Long-Term Systemic Bevacizumab for Recurrent Respiratory Papillomatosis.The Annals of otology, rhinology, and laryngology · 2024Article
- A phase I dose-finding trial of hyperthermic intraperitoneal docetaxel combined with cisplatin in patients with advanced-stage ovarian cancer.Journal of gynecologic oncology · 2024Article
- Sunitinib-related high-grade proteinuria and allograft dysfunction in a kidney recipient: a rare case report.BMC nephrology · 2022Article
- Unique Presentation of Bortezomib-Associated Thrombotic Microangiopathy Responsive to Therapeutic Plasma Exchange and Eculizumab Therapy.Hematology reports · 2022Article
- Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration.Clinical kidney journal · 2021Article
- Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients.Circulation research · 2021Review
- Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer.CEN case reports · 2021Article
- Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature.Current oncology (Toronto, Ont.) · 2021Review
- A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy.Frontiers in oncology · 2021Article
- Rapidly progressive glomerulonephritis caused by tegafur/gimeracil/oteracil resulted in diabetes nephropathy, in a patient with minor risk of diabetes nephropathy: a case report.CEN case reports · 2020Article
- Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use.Frontiers in medicine · 2020Article
- VEGF regulates local inhibitory complement proteins in the eye and kidney.The Journal of clinical investigation · 2017Article
- Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization.Cancer gene therapy · 2017Article
- Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Review
- Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options.Current treatment options in cardiovascular medicine · 2016Article
- Minimal change disease onset observed after bevacizumab administration.Clinical kidney journal · 2016Article
- Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives.International journal of women's health · 2016Review
- Molecular mechanisms of diabetic retinopathy: potential therapeutic targets.Middle East African journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Expanded clinical experience with the antivascular endothelial growth factor (VEGF) agents has come with increasing recognition of their renal adverse effects. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now established. Its manifestations include hypertension, proteinuria, and mainly glomerular thrombotic microangiopathy. Then, in nephrology practice, should we continue to perform kidney biopsy, and what should be done with the anti-VEGF agents in case of renal toxicity?
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.